Las cámaras agrarias

[ES] El trabajo doctoral está dirigido a estudiar el papel jurídico administrativo que han desempeñado las Cámaras Agrarias y su actualidad y futuro como Entidades corporativas. El objetivo del trabajo es el estudio de unas instituciones especialmente significadas en nuestra historia contemporánea rural. El análisis de su influencia en nuestro entorno agroganadero desde 1890 hasta hoy en día. Se desarrolla su evolución histórica social y normativa, el análisis constitucional y la singularidad en los diferentes Estatutos autonómicos, las peculiaridades que definen estas Corporaciones en su entorno jurídico. Se incluye una visión particularizada de las Cámaras Agrarias en nuestra Comunidad Autónoma de Castilla y León.Se aporta como instrumento de valor añadido, la experiencia de trabajo personal en estas Entidades de la autora, incorporando documentación y conocimientos que complementan de forma singularizada el trabajo de investigación. A estos efectos, se señala la escasa bibliografía y aporte documental previos existentes sobre la materia, factor que incide en la revalorización del presente estudio. El método utilizado ha consistido en el estudio de la evolución normativa y documental desde su nacimiento hasta el día de hoy, utilizando las bases documentales de las Administraciones Públicas tuteladoras de estas Corporaciones a lo largo de su existencia y las existentes en las Entidades objeto de estudio, Cámaras Agrarias locales y provinciales. desarrolla su evolución histórica social y normativa, el análisis constitucional y la singularidad en los diferentes Estatutos autonómicos, las peculiaridades que definen estas Corporaciones en su entorno jurídico. Se incluye una visión particularizada de las Cámaras Agrarias en nuestra Comunidad Autónoma de Castilla y León. Se aporta como instrumento de valor añadido, la experiencia de trabajo personal en estas Entidades de la autora, incorporando documentación y conocimientos que complementan de forma singularizada el trabajo de investigación. A estos efectos, se señala la escasa bibliografía y aporte documental previos existentes sobre la materia, factor que incide en la revalorización del presente estudio. El método utilizado ha consistido en el estudio de la evolución normativa y documental desde su nacimiento hasta el día de hoy, utilizando las bases documentales de las Administraciones Públicas tuteladoras de estas Corporaciones a lo largo de su existencia y las existentes en las Entidades objeto de estudio, Cámaras Agrarias locales y provinciales. El análisis de la situación actual, el estudio de la última normativa en esta materia, el progresivo deterioro de su papel corporativo, la apuesta decidida en nuestra Comunidad Autónoma por su existencia y los testimonios de los representantes sociales y políticos afectados por su situación, completan el análisis doctoral realizado

Elaboración de rúbricas para la evaluación de prácticas en las asignaturas de Organización de Empresas impartidas en el Grado en Relaciones Laborales y Recursos Humanos

Memoria ID-0259. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2014-2015

Actores de la cadena productiva que deben participar para prevenir el uso de clembuterol en la engorda del ganado bovino en México

El clembuterol, Químicamente se describe como polvo blanco, anhidro, muy soluble en agua y altamente estable a temperatura ambiente, su punto de fusión es de 174 a 175.5 ºC. También es un derivado sintético perteneciente a una clase de medicamentos análogos fisiológicamente a la adrenalina, tiene la capacidad de interactuar con receptores adrenérgicos,  generalmente  del  tipo  ß2    (β  agonista),  es  uno  de  los  modificadores metabólicos más conocido en el área de producción de carne, debido al alto grado residual que deja esta sustancia en los tejidos comestibles y sus posibles repercusiones en la salud pública. En este trabajo, se describen los principales actores de la cadena productiva en la engorda  de  ganado  que  deben  participar  para  prevenir  el  uso  de  clembuterol.  La información fue recopilada de información científicas y publicaciones de las autoridades competentes, tales como: SENASICA, SAGARPA, COFEPRIS y Ley Federal de Sanidad Animal

Memorias del 4o. coloquio de estudios sobre juegos de rol

Aquí se recopilan las ponencias recibidas para ser publicadas en el 4o. Coloquio de estudios sobre juegos de rol (2019), realizado en el Tec de Monterrey campus Puebla el 4 y 5 de julio de 2019. Únicamente se publican las ponencias cuyos autores dieron permiso explícito para ello y que facilitaron copia de su trabajo. Los resúmenes de las ponencias pasaron por un proceso de revisión doble ciego para ser admitidas en el coloquio. Editor: Mauricio Rangel Jiménezhttps://digitalcommons.njit.edu/stemresources/1021/thumbnail.jp

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis.

Journal Article;OBJECTIVE Endogenous uveitis is a major cause of visual loss mediated by the immune system. The protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene encodes a lymphoid-specific phosphatase that plays a key role in T-cell receptor (TCR) signaling. Two independent functional missense single nucleotide polymorphisms (SNPs) located within the PTPN22 gene (R263Q and R620W) have been associated with different autoimmune disorders. We aimed to analyze for the first time the influence of these PTPN22 genetic variants on endogenous non-anterior uveitis susceptibility. METHODS We performed a case-control study of 217 patients with endogenous non-anterior uveitis and 718 healthy controls from a Spanish population. The PTPN22 polymorphisms (rs33996649 and rs2476601) were genotyped using TaqMan allelic discrimination assays. The allele, genotype, carriers, and allelic combination frequencies were compared between cases and controls with χ(2) analysis or Fisher's exact test. RESULTS Our results showed no influence of the studied SNPs in the global susceptibility analysis (rs33996649: allelic P- value=0.92, odds ratio=0.97, 95% confidence interval=0.54-1.75; rs2476601: allelic P- value=0.86, odds ratio=1.04, 95% confidence interval=0.68-1.59). Similarly, the allelic combination analysis did not provide additional information. CONCLUSIONS Our results suggest that the studied polymorphisms of the PTPN22 gene do not play an important role in the pathophysiology of endogenous non-anterior uveitis.Ye

A case of acute lumphoblastic leukemia presenting with migratory superficial thrombophlebitis

Venöz tromboemboHzm ve maliyn hastalıklar arasında bir ilişki olduğu yapılan çalışmalarda gösterilmiştir. Maliyniteli olguların %5-10'unda; derin ven trombozu, arteriyel tromboz, gezici tromboflebit, pulmoner emboli ve non-bakteriyel trombotik endokardit gibi tromboembolik olaylar gelişmektedir. Genellikle ileri evre kanserlerde görülen tromboz bazen kansere ait bulgular ortaya çıkmadan ilk bulgu olarak da saptanabilir. Sağ ayak bileği travması sonrası başvuran, ateş ve hiperlökositoz görülerek yatırılan olguda sağ bacak diz üstü iç yan bölgede yüzeyel tromboflebit olduğu saptandı. Hastanın yapılan periferik yaymasında %90 blast formunda lenfositler görüldü. Periferik kandan yapılan immünfenotipleme sonucu Pre B hücreli ALL ile uyumlu bulundu (CD-19 %93.74, CDL5 %98.73,CD-34 %87.58, CD-22 %63.59, CD-10 negatif). Yapılan kemik iliği biyopsisinde pre B hücreli ALL tanısı teyit edildi. Pre B hücreli lösemi tanısı alan hastanın ikinci günde sol bacakta da tromboflebit gelişti. Antitrombin III (%95) ve fibrinojen (3.7g/dL) düzeyleri normal olan, derin ven trombozu saptanmayan olgu nadir görülmesi ve gezici süperfisiyel tromboflebit ile akut lenfoblastik lösemi arasındaki ilişkiyi düşündürmesi açısından sunulmaya uygun bulunmuştur.The relationship between malignant diseases and venous thromboembolism was shown by different studies. In 10% of patients with malignancy thromboembolic events such as deep vein thrombosis, pulmonary emboli and nonthrombotic endocardit may occur. In high grade cancers, usually before the clinical findings, deep vein thrombosis may be diagnosed. The case who was admitted for right ankle trauma was hospitalized with fever and hyperleucocytosis. A peripheral blood examination revealed lymphocytosis with 90% blast cells. The patient was diagnosed as pre B-cell ALL by the immunophenotype (CD-19 %93.74, CD-45 %98.73, CD-34 %87.58, CD-22 %63.59, CD-10 negative). Pre B-cell ALL diagnosis was confirmed with bone marrow biopsy. The patient developed thrombophlebitis in left leg by the second day of the hospitalization. Antithrombin III (95%) and fibrinogen (3.7 g/dL) levels were in normal ranges and there was no evidence for deep vein thrombosis. The case is presented aş_it-,is d mre condition which indicates a possible association between migratory superficial thrombophlebitis and B-cell acute lymhoblastic leukemia

Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy.

The genetic cause of hypertrophic cardiomyopathy remains unexplained in a substantial proportion of cases. Formin homology 2 domain containing 3 (FHOD3) may have a role in the pathogenesis of cardiac hypertrophy but has not been implicated in hypertrophic cardiomyopathy. This study sought to investigate the relation between FHOD3 mutations and the development of hypertrophic cardiomyopathy. FHOD3 was sequenced by massive parallel sequencing in 3,189 hypertrophic cardiomyopathy unrelated probands and 2,777 patients with no evidence of cardiomyopathy (disease control subjects). The authors evaluated protein-altering candidate variants in FHOD3 for cosegregation, clinical characteristics, and outcomes. The authors identified 94 candidate variants in 132 probands. The variants' frequencies were significantly higher in patients with hypertrophic cardiomyopathy (74 of 3,189 [2.32%]) than in disease control subjects (18 of 2,777 [0.65%]; p  FHOD3 is a novel disease gene in hypertrophic cardiomyopathy, accounting for approximately 1% to 2% of cases. The phenotype and the rate of cardiovascular events are similar to those reported in unselected cohorts. The FHOD3 gene should be routinely included in hypertrophic cardiomyopathy genetic testing panels

Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients

Introduction: Allergen immunotherapy (AIT) brings along changes in the immune system, restoring dendritic cell function, reducing T2 inflammation and augmenting the regulatory cell activation. Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, interferes with the immune system causing immune suppression during the first phase and over-activation in more advanced disease. We decided to explore the interaction of both in a real-world observational trial. Methods: We registered COVID-19 outcomes in patients with allergic disorders in Latin America, treated with and without AIT. The registry was conducted during the first 1.3 years of the pandemic, with most of the data collected before COVID-19 vaccination was concluded in most countries. Data collection was anonymous via a web-based instrument. Ten countries participated. Results: 630/1095 (57.6%) of the included patients received AIT. Compared to patients without AIT, those treated with AIT had a reduced risk ratio (RR) for COVID-19 lower respiratory symptoms (RR 0.78, 95% CI: 0.6703–0.9024; p = 0.001662) and need for oxygen therapy (RR 0.65, 95% CI: 0.4217–0.9992; p = 0.048). In adherent patients on maintenance sublingual immunotherapy/subcutaneous immunotherapy (SLIT/SCIT) the RR reduction was larger [RR = 0.6136 (95% CI 0.4623–0.8143; p < 0.001) and RR: 0.3495 (95% CI 0.1822–0.6701; p < 0.005), respectively]. SLIT was slightly more effective (NS). We excluded age, comorbidities, level of health care attendance, and type of allergic disorder as confounders, although asthma was related to a higher frequency of severe disease. When analyzing patients with allergic asthma (n = 503) the RR reduction favoring AIT was more pronounced with 30% for lower respiratory symptoms or worse (RR 0.6914, 95% CI 0.5264 to 0.9081, p = 0.0087) and 51% for need of oxygen therapy or worse (RR 0.4868, 95% CI 0.2829–0.8376, p = 0.0082). Among severe allergic patients treated with biologics (n = 24) only 2/24 needed oxygen therapy. There were no critical cases among them. Conclusion: In our registry AIT was associated with reduced COVID-19 severity